🔭 #LegislativeObservatory
@NFDI has participated in the association hearing by @bmftr_bund regarding the planned Research Data Act (#FDG, #Forschungsdatengesetz). In its statement, NFDI

1. welcomes the establishment of a German Center for Microdata (#DZM),
2. demands standardization of secure processing environments (#SPE) and
3. encourages additional steps towards the more general availability of #metadata.

Read the full statement here:
🇩🇪 https://www.nfdi.de/wp-content/uploads/2026/02/NFDI-eV_Stellungnahme-Forschungsdatengesetz-FDG_2026-02-10.pdf

🔭 #LegislativeObservatory
Concluding our series on the status of the 🇩🇪 #Digitalstrategie (see previous post https://nfdi.social/@nfdi4immuno/111719260750940903):

Research Data Act (#FDG, #Forschungsdatengesetz) [Page 89; Q73] @bmbf_bund is evaluating how to address the demands identified in the public consultation conducted 04/2023, there are plans for another round of stakeholder involvement. A final draft of the @Bundesregierung is scheduled for Q4/2024.

🇩🇪 https://dserver.bundestag.de/btd/20/098/2009821.pdf

NFDI4Immuno (@[email protected])

What is the current status of all the projects in the #Digitalstrategie of the 🇩🇪 @[email protected] ? Thanks to a "brief" inquiry (96 pages 😉) in the #Bundestag, we now have a broad overview, which includes: #OpenData, #DataCompetency, #EHDS, electronic health records (#EHR) for research, data infrastructure for university medicine, the Research Data Act (#FDG), #NFDI and #GaiaX. We will unpack some of them here this week, the complete document can be found under: 🇩🇪 https://dserver.bundestag.de/btd/20/098/2009821.pdf

Nationale Forschungsdateninfrastruktur (NFDI)

🔭 #LegislativeObservatory: The position of the #EUCouncil on the #EHDS (European Health #DataSpace) is now also available:

http://data.consilium.europa.eu/doc/document/ST-16048-2023-REV-1/EN/pdf

Key differences from the Parliament's position on secondary use of #HealthData are 1) no required opt-in for "genetic" data, but member states may impose additional restrictions [Art. 33 (5)]; 2) "other human molecular data" (Omics data) [Art. 33 (1) lit. ea] are treated equally to "genetic" data and need opt-in and 3) no opt-in for #Biobank data.

🔭 #LegislativeObservatory: #EuropeanParliament has just voted in favor of the #EHDS (European Health #DataSpace) compromise version of #ENVI and #LIBE , rejecting further amendments (ex. 555):

https://www.europarl.europa.eu/doceo/document/A-9-2023-0395_EN.html

Relevant changes for secondary use of #HealthData are 1) an opt-in requirement for sharing of genetic and #biobank data (Art. 33 (5a), Rec. 39a) and 2) allowing member states to impose further restrictions on data falling within Art. 9 #GDPR (Rec. 3a). #Trilog will start tomorrow!

🔭 #LegislativeObservatory: The Health Data Usage Act (#GDNG, Gesundheitsdatennutzungsgesetz) has been introduced into the @bundestag, first reading is next Thu. Single change vs. end-August draft (introduced at request of #Bundesrat) is the inclusion of data held for purposes of public health and quality assurance (Art. 9(2)(i) GDPR) into the list of data that healthcare facilities can process for intramural research without requiring explicit consent (§6 (1) GDNG).

🇩🇪 https://dip.bundestag.de/vorgang/gesetz-zur-verbesserten-nutzung-von-gesundheitsdaten-gesundheitsdatennutzungsgesetz-gdng/303310
DIP